48 articles
PRP trial
PRP trial (NCT05737173) is a completed phase 2 randomized trial at Queen Savang Vadhana Memorial Hospital, Thailand, comparing leukocyte-rich PRP, leukocyte-poor PRP, and corticosteroid injections for knee osteoarthritis, with WOMAC at 6 months as the primary outcome.
pSS study
pSS study: research on primary Sjögren's syndrome biomarkers, centered on the ASSESS cohort showing the interferon signature is driven by IFNα, plus MxA, BAFF, CXCL13, and lymphoma risk markers.
RPD trial
RPD trial (NCT00651625): University of New Mexico randomized controlled trial comparing the reciprocating procedure device safety syringe with a conventional syringe in 437 patients; RPD cut procedural pain, procedure time, and tissue trauma across arthrocentesis, injection, and anesthesia studies.
SELECT-AXIS 2 trial
SELECT-AXIS 2 (NCT04169373) is AbbVie's phase 3 program of upadacitinib 15 mg in axial spondyloarthritis; its nr-axSpA study showed ASAS40 45% vs 23% at week 14.
SELECT-BEYOND trial
SELECT-BEYOND (NCT02706847): AbbVie-funded phase 3 trial of upadacitinib 15/30 mg in rheumatoid arthritis refractory to biologic DMARDs; ACR20 65%/56% vs 28% placebo at week 12, 5-year extension data.
SELECT-EARLY trial
SELECT-EARLY (NCT02706873), a phase 3 SELECT-program trial of upadacitinib (Rinvoq), tested 15/30 mg once-daily monotherapy against methotrexate in 945 MTX-naive rheumatoid arthritis patients, showing superior efficacy through 5 years.
SIS trial
SIS trial: NCT04599127, a completed Mahidol University randomized trial of Mulligan mobilization with movement added to conventional physical therapy in shoulder impingement syndrome; 22 participants in Jakarta, no results posted.
SPIRIT-P1 trial
SPIRIT-P1 (NCT01695239) is Eli Lilly's phase III trial of ixekizumab, an IL-17A antibody, in biologic-naive active psoriatic arthritis; 417 patients, adalimumab reference, 156-week efficacy and safety follow-up.
SportMarkers study
SportMarkers (NCT03386981) is an observational study by IRCCS Ospedale Galeazzi-Sant'Ambrogio in Milan studying bone metabolism in 200 professional athletes by sport type, using bone turnover markers, hormones, and miRNAs; started 2016, recruiting.
T-REC study
T-REC (NCT06147128) is an Orsi Academy randomized blinded trial comparing proficiency-based progression with traditional training for robotic emergency conversion after vessel injury, in 48 Belgian surgical residents across four arms.
TEDIZOAM trial
TEDIZOAM (NCT03378427), Tedizolid Prolonged Treatment for Prosthetic Joint Infections, a prospective cohort study of prolonged tedizolid for orthopedic device infections, assessing tolerability and one-year remission.
TKACSI trial
The TKACSI trial is a registered clinical trial testing which corticosteroid drug, added to routine pain-control injections during knee replacement, best eases pain and recovery.
TME-HME trial
TME-HME (NCT07482527) is a not-yet-recruiting, single-blinded randomized trial at Cairo University testing thoracic versus hip mobility exercises added to core stabilization in 60 patients aged 40-60 with lumbar spondylosis.
TOSS trial
TOSS (Transtibial Osseointegration Study, NCT06636136) is a Walter Reed FDA pivotal trial testing off-label OPRA osseointegrated implants in 30 transtibial amputees, ages 22-65, with two-stage surgery and 60-month follow-up.
Triple IN trial
Triple IN (NCT01297959) was a Phase 3 randomized double-blind trial of topical E-101 Solution, a glucose oxidase and porcine myeloperoxidase antiseptic, versus saline to prevent incisional surgical site infections after elective colorectal surgery; 503 participants, completed 2015, results posted 2021.
WBVibration trial
WBVibration (NCT06330311) is a Madrid randomized controlled trial adding whole-body vibration to physiotherapy in 30 children with spastic cerebral palsy; it found no additional benefit over intensive physiotherapy alone.
WSL-Curodont trial
The WSL-Curodont trials are randomized controlled trials testing topical P11-4 (Curodont Repair), a self-assembling peptide that promotes remineralization, against fluoride varnish, placebo, or no treatment for arresting white spot lesions.
Xb&Nin trial
Xb&Nin (NCT06551870), Xbox Kinect Sports versus Nintendo Switch Sports: Chilean three-arm RCT in 45 inactive women aged 60-75 comparing 12 weeks of exergames against a control; Xbox Kinect Sports won on most outcomes.